| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 630 companies in the Biotechnology industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| May 28, 2026 | EQ Equillium, Inc. | Zedelmayer Christine63 | Sr. Vice President And COO | Sell | 95,833 | $2.79 | $267,209.34 | -27.7% | - | - | |
| May 27, 2026 | CORT Corcept Therapeutics Incorporated | Maduck Sean53 | See Remarks | Sell | 75,000 | $65.59 | $4,918,943.74 | -66.1% | - | - | |
| May 27, 2026 | CORT Corcept Therapeutics Incorporated | Lyon Joseph Douglas50 | See Remarks | Sell | 5,000 | $65.00 | $325,000.00 | -44.5% | - | - | |
| May 27, 2026 | SION Sionna Therapeutics, Inc. | Orbimed Advisors LLC67 | Director | Sell | 101 | $44.49 | $4,493.49 | - | - | - | |
| May 27, 2026 | SION Sionna Therapeutics, Inc. | Thompson Peter A.65 | Director | Sell | 101 | $44.49 | $4,493.49 | - | - | - | |
| May 27, 2026 | PLYX Polaryx Therapeutics, Inc. | Yang Alex Keun Mo | Chief Executive Officer | Buy | 88,453 | $4.07 | $360,003.71 | +0.4% | - | - | |
| May 26, 2026 | OTLK Outlook Therapeutics, Inc. | Hilzinger Kurt J | Director | Buy | 400,000 | $0.44 | $176,520.00 | +1,691% | - | - | |
| May 26, 2026 | OTLK Outlook Therapeutics, Inc. | Haddadin Yezan Munther | Director | Buy | 34,000 | $0.44 | $14,960.00 | +1,074% | - | - | |
| May 26, 2026 | OTLK Outlook Therapeutics, Inc. | Thurman Randy H | Director | Buy | 5,000 | $0.43 | $2,145.00 | +843.2% | - | - | |
| May 26, 2026 | EXEL Exelixis, Inc. | Aftab Dana | EVP, Research And Development | Sell | 43,451 | $50.35 | $2,187,757.85 | -6.8% | - | - | |
| May 26, 2026 | CNTN Canton Strategic Holdings, Inc. | Stetz Gary S. | Director | Sell | 100,351 | $3.43 | $343,882.44 | -6.5% | - | - | |
| May 26, 2026 | HOWL Werewolf Therapeutics, Inc. | Evnin Luke55 | Director | Sell | 191,762 | $0.45 | $86,560.29 | -7.1% | - | - | |
| May 22, 2026 | CVKD Cadrenal Therapeutics, Inc. | Pham Quang X49 | CEO And Chairman | Sell | 1,165 | $5.69 | $6,628.85 | -0.6% | - | - | |
| May 22, 2026 | MDGL Madrigal Pharmaceuticals, Inc. | Levy Richard S | Director | Sell | 5,682 | $515.44 | $2,928,716.43 | -1.8% | - | - | |
| May 22, 2026 | HCWB Hcw Biologics Inc. | Byam Rebecca | Chief Financial Officer | Buy | 14,235 | $1.41 | $20,000.18 | +33.1% | - | - | |
| May 22, 2026 | HCWB Hcw Biologics Inc. | Garrett Scott T | Director | Buy | 177,936 | $1.41 | $250,000.08 | +697.7% | - | - | |
| May 22, 2026 | HCWB Hcw Biologics Inc. | Wong Hing C | Chief Executive Officer | Buy | 113,879 | $1.41 | $160,000.00 | +22.7% | - | - | |
| May 22, 2026 | SER Serina Therapeutics, Inc. | Venkatesan Jay | Director | Buy | 589 | $1.78 | $1,048.42 | New | - | - | |
| May 22, 2026 | PRTA Prothena Corporation Plc | Scully William P | 10% Owner | Buy | 100,000 | $9.81 | $981,300.00 | +13.6% | - | - | |
| May 20, 2026 | PHVS Pharvaris N.V. | Bjork Elisabeth | Director | Sell | 10,000 | $29.32 | $293,166.00 | -39.7% | - | - | |
| May 20, 2026 | IMVT Immunovant, Inc. | Pande Atul74 | Director | Sell | 6,000 | $32.00 | $192,000.00 | -4.9% | - | - | |
| May 20, 2026 | RPRX Royalty Pharma Plc | Urist Marshall73 | EVP, Research &Investments | Sell | 13,684 | $52.75 | $721,837.84 | -42.9% | - | - | |
| May 20, 2026 | KLRS Kalaris Therapeutics, Inc. | Akkaraju Srinivas81 | Director, 10% Owner | Buy | 244,300 | $4.83 | $1,179,969.00 | +12.3% | - | - | |
| May 20, 2026 | BCDA Biocardia, Inc. | Altman Peter46 | President And CEO | Buy | 1,700 | $0.92 | $1,570.00 | +0.3% | - | - | |
| May 20, 2026 | HOWL Werewolf Therapeutics, Inc. | Evnin Luke55 | Director | Sell | 171,049 | $0.45 | $76,363.35 | -5.2% | - | - |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.